Windtree Therapeutics Company Profile (NASDAQ:WINT)

About Windtree Therapeutics (NASDAQ:WINT)

Windtree Therapeutics logoWindtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company's technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company's core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:WINT
  • CUSIP: 25466840
  • Web: www.windtreetx.com/
Capitalization:
  • Market Cap: $2.59 million
  • Outstanding Shares: 13,994,000
Average Prices:
  • 50 Day Moving Avg: $0.21
  • 200 Day Moving Avg: $0.75
  • 52 Week Range: $0.18 - $3.50
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.56
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $3.23 million
  • Price / Sales: 0.80
  • Book Value: ($3.05) per share
  • Price / Book: -0.06
Profitability:
  • EBITDA: ($28,340,000.00)
  • Net Margins: -588.67%
  • Return on Assets: -308.95%
Debt:
  • Debt-to-Equity Ratio: -1.09%
  • Current Ratio: 0.97%
  • Quick Ratio: 0.97%
Misc:
  • Average Volume: 260,729 shs.
  • Beta: 1.98
  • Short Ratio: 2.46
 

Frequently Asked Questions for Windtree Therapeutics (NASDAQ:WINT)

What is Windtree Therapeutics' stock symbol?

Windtree Therapeutics trades on the NASDAQ under the ticker symbol "WINT."

How were Windtree Therapeutics' earnings last quarter?

Windtree Therapeutics Inc (NASDAQ:WINT) issued its earnings results on Monday, August, 21st. The company reported ($0.76) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.99) by $0.23. The firm earned $1.15 million during the quarter, compared to analysts' expectations of $0.40 million. View Windtree Therapeutics' Earnings History.

Where is Windtree Therapeutics' stock going? Where will Windtree Therapeutics' stock price be in 2017?

2 brokerages have issued 1-year price objectives for Windtree Therapeutics' stock. Their predictions range from $8.00 to $8.00. On average, they expect Windtree Therapeutics' share price to reach $8.00 in the next twelve months. View Analyst Ratings for Windtree Therapeutics.

Who are some of Windtree Therapeutics' key competitors?

Who are Windtree Therapeutics' key executives?

Windtree Therapeutics' management team includes the folowing people:

  • John R. Leone, Independent Chairman of the Board
  • Craig Fraser, President, Chief Executive Officer, Director
  • John A. Tattory, Chief Financial Officer, Senior Vice President
  • Mary B. Templeton Esq., Senior Vice President, General Counsel and Corporate Secretary
  • Kathryn A. Cole, Senior Vice President - Human Resources
  • Steven G. Simonson M.D., Senior Vice President and Chief Development Officer
  • William C. Roberts, Vice President - Investor Relations and Corporate Communications
  • Michael L. Magee, Vice President - Technical Operations
  • Mahady M. Joseph, Independent Director
  • Bruce A. Peacock, Independent Director

How do I buy Windtree Therapeutics stock?

Shares of Windtree Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Windtree Therapeutics' stock price today?

One share of Windtree Therapeutics stock can currently be purchased for approximately $0.19.


MarketBeat Community Rating for Windtree Therapeutics (NASDAQ WINT)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  75 (Vote Outperform)
Underperform Votes:  61 (Vote Underperform)
Total Votes:  136
MarketBeat's community ratings are surveys of what our community members think about Windtree Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Windtree Therapeutics (NASDAQ:WINT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $8.00 (4,224.32% upside)
Consensus Price Target History for Windtree Therapeutics (NASDAQ:WINT)
Price Target History for Windtree Therapeutics (NASDAQ:WINT)
Analysts' Ratings History for Windtree Therapeutics (NASDAQ:WINT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/30/2017Stifel NicolausDowngradeBuy -> HoldHighView Rating Details
10/30/2016HC WainwrightSet Price TargetBuy$8.00N/AView Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for Windtree Therapeutics (NASDAQ:WINT)
Earnings by Quarter for Windtree Therapeutics (NASDAQ:WINT)
Earnings History by Quarter for Windtree Therapeutics (NASDAQ WINT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/21/2017Q2 2017($0.99)($0.76)$0.40 million$1.15 millionViewN/AView Earnings Details
5/15/2017Q1 2017($1.37)$0.22 millionViewN/AView Earnings Details
8/10/2016Q2($1.64)($1.29)$0.08 million$0.11 millionViewN/AView Earnings Details
5/12/2016Q116($1.58)($1.70)$0.08 millionViewListenView Earnings Details
3/24/2016Q4($0.70)($1.26)$0.07 million$0.66 millionViewListenView Earnings Details
8/10/2015Q215($0.13)($0.13)$0.45 million$0.08 millionViewListenView Earnings Details
3/16/2015Q414($0.14)($0.12)$0.54 million$1.18 millionViewN/AView Earnings Details
11/6/2014($0.15)($0.13)$0.50 million$0.53 millionViewN/AView Earnings Details
8/5/2014Q2 14($0.15)($0.12)$0.26 million$1.09 millionViewN/AView Earnings Details
5/8/2014Q114($0.13)($0.14)$2.69 million$0.03 millionViewN/AView Earnings Details
3/13/2014Q413($0.16)($0.16)$0.36 million$0.07 millionViewN/AView Earnings Details
11/12/2013Q3($0.20)($0.22)$0.11 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.28)($0.18)$10.00 million$0.18 millionViewN/AView Earnings Details
11/8/2012Q312($0.23)($0.31)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Windtree Therapeutics (NASDAQ:WINT)
Current Year EPS Consensus Estimate: $-2.460 EPS
Next Year EPS Consensus Estimate: $-0.330 EPS

Dividends

Dividend History for Windtree Therapeutics (NASDAQ:WINT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Windtree Therapeutics (NASDAQ:WINT)
Insider Ownership Percentage: 1.30%
Institutional Ownership Percentage: 36.81%
Insider Trades by Quarter for Windtree Therapeutics (NASDAQ:WINT)
Institutional Ownership by Quarter for Windtree Therapeutics (NASDAQ:WINT)
Insider Trades by Quarter for Windtree Therapeutics (NASDAQ:WINT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/28/2016Craig FraserInsiderBuy7,500$2.05$15,375.00View SEC Filing  
2/19/2013John R LeoneDirectorBuy3,000$2.88$8,640.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Windtree Therapeutics (NASDAQ:WINT)
Latest Headlines for Windtree Therapeutics (NASDAQ:WINT)
Source:
Loading headlines, please wait.

Social

Chart

Windtree Therapeutics (WINT) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.